Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

CHANGE OF EXECUTIVE DIRECTOR

The Board announces that with effect from 13 July 2026:

(1) Mr. Liu Lihao has resigned as an executive Director; and

(2) Mr. Yang Feng has been appointed as an executive Director.

CHANGE OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of Kaisa Health Group Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. Liu Lihao ("**Mr. Liu**") has resigned as an executive Director due to his other work arrangement with effect from 13 July 2026.

Mr. Liu has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Following the resignation of Mr. Liu, the Board is pleased to announce that Mr. Yang Feng ("**Mr. Yang**") has been appointed as an executive Director.

The biographical details of Mr. Yang are set out below:

Mr. Yang

Mr. Yang Feng (楊峰先生), aged 52, is the president of Qinghai Pharmaceutical Co., Ltd.* (青海製藥有限公司) ("**Qinghai Pharmaceutical**"), a subsidiary of the Company, Mr. Yang is responsible for the overall operation and management of Qinghai Pharmaceutical. He joined Qinghai Pharmaceutical in 2021 and has successively served as its chief strategic officer, vice chairman, senior vice president, and president. Mr. Yang obtained his bachelor's degree from Xinjiang Medical University.

Mr. Yang has entered into a service contract with the Company for a term of three years from 13 July 2026 to 12 July 2029 (both dates inclusive). Mr. Yang will receive director's emoluments from the Company in the amount of HK$100,000 before tax per annum. Mr. Yang will hold office until the next following annual general meeting of the Company and will be subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the Listing Rules and the bye-laws of the Company.

As at the date of this announcement, Mr. Yang does not have any interest in or is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, as of the date of this announcement, Mr. Yang (i) has not held any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement or any other major appointments and professional qualifications; (ii) does not hold any other positions in the Company and other members of the Group; and (iii) does not have any other relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (within the meaning of the Listing Rules) of the Company.

Save as disclosed above, as of the date of this announcement, Mr. Yang confirmed that there is no other information which requires to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules nor is there any other matter regarding his appointment that need to be brought to the attention of the shareholders of Company and/or the Stock Exchange.

* *The English translation of the Chinese name is for identification purpose only*

The Board would like to take this opportunity to express its gratitude to Mr. Liu for his contributions during his tenure of office and to welcome Mr. Yang in joining the Board.

By Order of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman and Executive Director

Hong Kong, 13 July 2026

As at the date of this announcement, the Board comprises Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Ms. Luo Tingting, Mr. Xie Binhong, Mr. Yang Feng and Mr. Ye Haoda as executive Directors; and Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying as independent non-executive Directors.